Patents by Inventor Karen Brown
Karen Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220395421Abstract: A vacuum massager includes a housing having an upper portion and a lower portion, and a cup attachment arranged to be removably received on the lower portion of the housing. An air pump is disposed within the housing in fluid communication with the cup attachment for generating suction therein, such that contact of the cup attachment with a user's skin creates a vacuum within the cup attachment. A controller is disposed within the housing in electrical communication with the air pump. The vacuum massager further includes a cooling attachment interchangeable with the cup attachment and arranged to be removably received on the lower portion of the housing in electrical communication with the controller for cooling the user's skin.Type: ApplicationFiled: November 9, 2020Publication date: December 15, 2022Applicant: FKA DISTRIBUTING CO., LLCInventor: Karen BROWN
-
Patent number: 11473114Abstract: The present invention discloses processes for obtaining a color from an algal biomass. The process includes subjecting an algal biomass to cavitation, thus at least partially disrupting cells of the algal biomass and extracting color from the disrupted, algal biomass.Type: GrantFiled: April 26, 2018Date of Patent: October 18, 2022Assignee: ARCHER DANIELS MIDLAND COMPANYInventors: Paul Bloom, Karen Brown
-
Publication number: 20220184198Abstract: Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.Type: ApplicationFiled: January 24, 2022Publication date: June 16, 2022Applicant: Phibro Animal Health CorporationInventors: Peter Winter, Karen Brown, Michelle Mathiesen, Hailong Guo, Jeremy Griffel, Sam Christenberry, Meghan Quinn, Hector Cervantes, Bereket Zekarias
-
Patent number: 11000585Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: GrantFiled: March 14, 2019Date of Patent: May 11, 2021Assignee: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20210102228Abstract: The present invention discloses processes for obtaining a color from an algal biomass. The process includes subjecting an algal biomass to cavitation, thus at least partially disrupting cells of the algal biomass and extracting color from the disrupted, algal biomass.Type: ApplicationFiled: April 26, 2018Publication date: April 8, 2021Applicant: Archer Daniels Midland CompanyInventors: Paul Bloom, Karen Brown
-
Patent number: 10918711Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: GrantFiled: April 17, 2019Date of Patent: February 16, 2021Assignee: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20190247490Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: April 17, 2019Publication date: August 15, 2019Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20190231864Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: March 14, 2019Publication date: August 1, 2019Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Patent number: 10279031Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: GrantFiled: May 11, 2017Date of Patent: May 7, 2019Assignee: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20170340729Abstract: Disclosed herein are embodiments of an immunogenic composition for porcine epidemic diarrhea virus, and a method for making the immunogenic composition. Also disclosed is a method for administrating the immunogenic composition to a subject in need thereof. The immunogenic composition comprises PEDV proteins and/or antigens from one or more strains of PEDV, and may additionally comprise proteins and/or antigens from one or more additional porcine pathogens, such as PRRSV. Additionally disclosed in a combination comprising a PEDV immunogenic composition as disclosed herein, and an immunogenic composition or other therapeutic composition directed toward an additional porcine pathogen.Type: ApplicationFiled: August 8, 2017Publication date: November 30, 2017Applicants: MJ Biologics, Inc., Phibro Animal Health CorporationInventors: Byoung-Kwan Kim, Karen Brown, Larry Miller
-
Publication number: 20170326226Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: May 11, 2017Publication date: November 16, 2017Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20070205890Abstract: The arrangement of the present invention allows for a proximity warning system that can indicate the presence of an identified person, animal or object within the range of a sensor. In one application, this invention will warn hunters that an identified person, animal or object is within the field of fire of the weapon.Type: ApplicationFiled: March 6, 2006Publication date: September 6, 2007Inventor: Karen Brown
-
Publication number: 20050232948Abstract: Disclosed herein is a serum-based adjuvanted vaccine which is substantially free of non-host albumin and the use thereof in reducing or preventing post-vaccination systemic reactions.Type: ApplicationFiled: September 2, 2003Publication date: October 20, 2005Inventors: Kristina Hennessy, Karen Brown, Jennifer Lane, Sandra Trump
-
Publication number: 20050186227Abstract: A Neospora caninum vaccine comprising tissue culture grown Neospora and methods of making and using said vaccines. Neospora caninum vaccines described include those containing whole Neospora tachyzoites, extracts of Neospora tachyzoites and protective antigen subunits of Neospora tachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.Type: ApplicationFiled: April 28, 2005Publication date: August 25, 2005Inventors: Leszek Choromanski, Karen Brown
-
Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
Publication number: 20050025846Abstract: A method for producing a therapeutic treatment effect by a biologically active macromolecule through topical application to the skin of a human or other mammal is provided. One step of the method is providing a composition which includes the biologically active macromolecule and at least one essential oil. The biologically active macromolecule is present in an amount to produce the therapeutic treatment effect, and the essential oil is present in an amount to effect transdermal delivery of the biologically active macromolecule. The following step is applying the composition onto the skin of a human or other mammal to effectuate the transdermal delivery of the biologically active macromolecule evidenced by a resulting therapeutic treatment effect.Type: ApplicationFiled: July 7, 2004Publication date: February 3, 2005Inventors: Harold Brown, Karen Brown -
Patent number: D589387Type: GrantFiled: August 7, 2008Date of Patent: March 31, 2009Assignee: Homedics Group Ltd.Inventor: Karen Brown
-
Patent number: D600581Type: GrantFiled: August 7, 2008Date of Patent: September 22, 2009Assignee: Homedics Group Ltd.Inventors: Karen Brown, Adam Clark
-
Patent number: D969333Type: GrantFiled: November 9, 2020Date of Patent: November 8, 2022Assignee: FKA Distributing Co., LLCInventor: Karen Brown
-
Patent number: D977128Type: GrantFiled: April 9, 2021Date of Patent: January 31, 2023Assignee: FKA Distributing Co., LLCInventor: Karen Brown
-
Patent number: D1024348Type: GrantFiled: September 28, 2022Date of Patent: April 23, 2024Assignee: FKA Distributing Co., LLCInventor: Karen Brown